Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Two-part, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of APG777 in Patients With Moderate-to-severe Atopic Dermatitis

NCT06395948 is registered in ClinicalTrials.gov with Apogee Therapeutics, Inc. as lead sponsor.

NCT NCT06395948
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06395948 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Two-part, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of APG777 in Patients With Moderate-to-severe Atopic Dermatitis
Lead sponsor
Apogee Therapeutics, Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
April 29, 2024
Completion date
June 30, 2028
Enrollment
470 (actual)
Sites
94

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis